Showing results (111-120 of 623) with videos related to
Sort By:
Pageof 63
Nuclear Medicine and Biology|April 18, 2021
Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancerMagdalena Staniszewska, Janette Iking, Katharina Lückerath, et al.Nature Reviews. Clinical Oncology|February 6, 2019
The beginning of the end for conventional RECIST - novel therapies require novel imaging approachesMirjam Gerwing, Ken Herrmann, Anne Helfen, et al.Quantitative Imaging in Medicine and Surgery|July 17, 2023
DOTATOC PET/CT imaging of a typical carcinoid tumor in a human ex-vivo perfused lung lobeAlexis Slama, Benedikt M Schaarschmidt, Özlem Okumus, et al.Oncology Research and Treatment|November 24, 2021
The Future Role of PET Imaging in Metastatic Breast CancerKim M Pabst, Thomas Decker, David Kersting, et al.Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|May 1, 2020
Radiomics Analysis of Multiparametric PET/MRI for N- and M-Staging in Patients with Primary Cervical CancerLale Umutlu, Felix Nensa, Aydin Demircioglu, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 13, 2023
Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?Benedikt Feuerecker, Clemens Kratochwil, Hojjat Ahmadzadehfar, et al.European Urology Oncology|April 25, 2019
Theranostics for Advanced Prostate Cancer: Current Indications and Future DevelopmentsAndrea Farolfi, Wolfgang Fendler, Amir Iravani, et al.Data in Brief|March 5, 2021
Insights into immunometabolism: A dataset correlating the 18FDG PET/CT maximum standard uptake value of the primary tumor with the CCL18 serum level in non-small cell lung cancerTugba Dönmez, Kerstin Höhne, Gernot Zissel, et al.European Journal of Nuclear Medicine and Molecular Imaging|February 6, 2017
18F-FDG PET/MRI in patients suffering from lymphoma: how much MRI information is really needed?Julian Kirchner, Cornelius Deuschl, Johannes Grueneisen, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 19, 2019
In Vitro and In Vivo Characterization of an 18F-AlF-Labeled PSMA Ligand for Imaging of PSMA-Expressing XenograftsSusanne Lütje, Gerben M Franssen, Ken Herrmann, et al.Pageof 63